LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
-
F. Sabatel-Pérez [1] ; Álvaro García Ropero ; Carlos G. Santos Gallego ; Mohammad Urooj Zafar ; Juan José Badimón
-
[1] (1) Atherothrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574, United States (2) Cardiology Deparment, Complejo Hospitalario de Toledo, Toledo, Spain
-
- Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 55, Nº. 5, 2019 (Ejemplar dedicado a: Mayo), págs. 329-344
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Atherosclerotic cardiovascular disease is the leading cause of death all over the world. Its etiopathogenesis involves many correlated processes, with hypercholesterolemia being one of the main risk factors. Several large clinical trials have established the association between low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular events. With the aim to take control over high LDL-C levels, several drugs with different targets in the cholesterol pathway have been developed. Statins are the cornerstone of pharmacological lipid-lowering treatment, although they are not always successful in attaining the recommended LDL-C levels. Therefore, newer and more potent therapies have been developed, being prominent among them ezetimibe and especially the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Recent trials with these new therapies have reaffirmed the theory of 'the lower, the better' when it comes to LDL-C levels, and 'the earlier, the better' when it comes to atherosclerotic physiopathology. Copyright © 2019 Clarivate Analytics.
